CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company, on Thursday released its first-quarter financial results and provided various business highlights.
The company specializes in developing RNA-targeted therapies to upregulate gene expression to effectively treat genetic diseases.
Q1 2026:
The company reported a net loss of $18.33 million, or $0.32 per share, in Q1 2026, while in the same period of 2025, the net loss was $12.43 million, or $0.62 per share.
Research and development expenses (R&D) were $10.16 million, relatively stable compared to $10.15 million in the previous year.
Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $99.21 million.
Business Updates:
CAMP4 submitted a regulatory filing in Australia to enable a Phase 1/2 clinical trial for CMP-002 in the second half of 2026. CMP-002, a first-in-class treatment for SYNGAP1-related disorders, was also granted an orphan drug designation by the European Medicines Agency (EMA) and filed to receive an orphan drug designation from the FDA.
The company also began a collaboration with CURE SYNGAP for the ProMMis study to determine the natural history of SYNGAP1-related disorders and to develop effective therapies.
A preprint of a pioneering study was submitted, outlining regRNA capture sequencing to create the largest catalog of regRNAs.
CAMP is currently trading at $4.27, down 1.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.